Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 31 Linguagem: Inglês

10.1200/jco.20.01652

ISSN

1527-7755

Autores

Andrea B. Apolo, Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Seth M. Steinberg, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Guerrero Díaz, Marissa Mallek, Nicole N. Davarpanah, Rene Costello, Jane B. Trepel, Min-Jung Lee, Maria J. Merino, Mohammadhadi Bagheri, Paul Monk, William D. Figg, James L. Gulley, Piyush K. Agarwal, Vladimir Valera, Heather J. Chalfin, Jennifer Jones, Howard Streicher, James R. Wright, Yang‐Min Ning, Howard L. Parnes, William L. Dahut, Donald P. Bottaro, Primo N. Lara, Biren Saraiya, Sumanta K. Pal, Mark N. Stein, Amir Mortazavi,

Tópico(s)

Renal cell carcinoma treatment

Resumo

We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances.

Referência(s)